THE FDA HAS OFFICIALLY REMOVED ZHEJIANG HUAHAI PHARMACEUTICAL FROM IMPORT ALERT Somerset, NJ, November 15, 2021 – Solco is pleased to announce that the FDA has lifted the ImportAlert (IA) 66-40, “Detention Without Physical Examination of Drugs From Firms Which Have Not MetDrug GMPs”, Published Date: 11/12/2021, from Zhejiang Huahai Pharmaceutical Co. Ltd., at CoastalIndustrial
Read more
August 11, 2022 SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR TADALAFIL TABLETS SOMERSET, NJ — Solco Healthcare announces its FDA approval and availability of Tadalafil tablets, 2.5mg, 5mg, 10mg and 20mg, which are AB-rated generics equivalent to Cialis® and Adcirca® by Eli Lily. Tadalafil 2.5mg, 5mg, 10mg and 20mg tablets are indicated for the treatment
Read more
September 1, 2022 SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR NEBIVOLOL TABLETS SOMERSET, NJ — Solco Healthcare is proud to announce the FDA approval on April 7, 2022 and September 2022 availability of Nebivolol tablets, 2.5mg, 5mg, 10mg and 20mg an AB-rated equivalent to Bystolic® by Allergan, Inc. Nebivolol is a beta-adrenergic blocking agent indicated
Read more
SOLCO HEALTHCARE US, RECEIVES FDA APPROVAL FOR GLYCOPYRROLATE INJECTION, 0.2 mg/mL CRANBURY, NJ — Solco Healthcare announces its FDA approval for Glycopyrrolate Injection, 0.2mg/mL, which is an AP-rated equivalent to Robinul® by Hikma. “We are very pleased to have received FDA approval for Glycopyrrolate injection. This approval represents a new chapter for Solco, as we enter
Read more